Stock BEAM BEAM THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Beam Therapeutics Inc.

Equities

BEAM

US07373V1052

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-13 pm EDT 		5-day change 1st Jan Change
24.02 USD +12.98% Intraday chart for Beam Therapeutics Inc. +5.44% -11.76%
May. 07 Beam Therapeutics Shares Fall After Q1 Revenue Misses Estimates MT
May. 07 Beam Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases, as well as immunology/oncology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301 and BEAM-201. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents. BEAM-201 is an anti-CD7 CAR-T product candidate.

Number of employees: 346

Sales per Business

USD in Million2022Weight2023Weight Delta
Genetic Medicines
100.0 %
61 100.0 % 378 100.0 % +520.01%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
61 100.0 % 378 100.0 % +520.01%

Managers

Managers TitleAgeSince
John Evans CEO
 Chief Executive Officer 46 16-12-31
Giuseppe Ciaramella PSD
 President 55 18-01-31
Terry-Ann Burrell DFI
 Director of Finance/CFO 47 19-07-31
Gopi Shanker CTO
 Chief Tech/Sci/R&D Officer - 23-03-20
Amy Simon CTO
 Chief Tech/Sci/R&D Officer 60 21-03-14
Manmohan Singh CTO
 Chief Tech/Sci/R&D Officer 59 18-06-30
Brian Riley PRN
 Corporate Officer/Principal 47 19-08-31
Susan O'Connor HRO
 Human Resources Officer 61 17-07-31
Christine Bellon LAW
 General Counsel 59 19-03-31
Suzanne Fleming AUD
 Comptroller/Controller/Auditor 63 19-01-31

Members of the board

Members of the board TitleAgeSince
Graham Cooper BRD
 Director/Board Member 54 19-10-09
John Maraganore BRD
 Director/Board Member 60 21-11-04
Mark Fishman BRD
 Director/Board Member 73 18-04-30
Kristina Burow BRD
 Director/Board Member 50 17-05-31
Kathleen Walsh BRD
 Director/Board Member 68 21-01-09
John Evans CEO
 Chief Executive Officer 46 16-12-31
Christi L. Shaw BRD
 Director/Board Member 57 Dec. 13
Carole Ho BRD
 Director/Board Member 51 18-11-14

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 82,311,067 81,061,692 ( 98.48 %) 0 98.48 %

Shareholders

NameEquities%Valuation
ARK Investment Management LLC
10.02 %
8,182,174 10.02 % 177 M $
Vanguard Fiduciary Trust Co.
9.281 %
7,578,768 9.281 % 164 M $
BlackRock Advisors LLC
7.608 %
6,212,853 7.608 % 134 M $
STATE STREET CORPORATION
5.653 %
4,616,358 5.653 % 100 M $
Morgan Stanley Investment Management, Inc.
5.124 %
4,184,342 5.124 % 90 M $
Farallon Capital Management LLC
5.028 %
4,105,753 5.028 % 89 M $
Fidelity Management & Research Co. LLC
4.598 %
3,755,010 4.598 % 81 M $
Temasek Holdings Pte Ltd.
3.767 %
3,076,117 3.767 % 66 M $
Nikko Asset Management Americas, Inc.
2.892 %
2,361,817 2.892 % 51 M $
Milky Way Investments Group Ltd.
2.874 %
2,346,934 2.874 % 51 M $

Holdings

NameEquities%Valuation
PRIME MEDICINE, INC.
1.34%
 1,608,337 1.34% 6,915,849 $

Company contact information

Beam Therapeutics, Inc.

238 Main Street 9th floor

02142-1016, Cambridge

+

http://www.beamtx.com
address Beam Therapeutics Inc.(BEAM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Beam Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
24.02 USD
Average target price
48.38 USD
Spread / Average Target
+101.43%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BEAM THERAPEUTICS INC. Stock Beam Therapeutics Inc.
-11.76% 1.9B
MODERNA, INC. Stock Moderna, Inc.
+26.37% 48.16B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.01% 41.73B
LONZA GROUP AG Stock Lonza Group AG
+42.44% 41.03B
CELLTRION, INC. Stock Celltrion, Inc.
-5.31% 28.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.34% 25.59B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.69% 18.96B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+6.23% 12.92B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.99% 12.03B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.38% 11.77B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Company Beam Therapeutics Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW